Justin Rectenwald

Mr. Justin Rectenwald

University of North Carolina at Chapel Hill

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2020 in Cell Chemical Biology
Verified
Journal Article
Closed access
FPFrances Potjewyd
Frances Potjewyd
ATAnne-Marie W. Turner
Anne-Marie W. Turner
JBJoshua Beri
Joshua Beri
JRJustin Rectenwald
Justin Rectenwald
JNJacqueline L. Norris-Drouin
Jacqueline L. Norris-Drouin
LJLindsey I. James
Lindsey I. James

1 July 2019 in SLAS Discovery
Verified
Journal Article
Open access
PDF file
JRJustin Rectenwald
Justin Rectenwald
PHP. Brian Hardy
P. Brian Hardy
JNJacqueline L. Norris-Drouin
Jacqueline L. Norris-Drouin
SCStephanie H. Cholensky
Stephanie H. Cholensky
LJLindsey I. James
Lindsey I. James
KPKenneth H. Pearce
Kenneth H. Pearce
Chromatin regulatory complexes localize to specific sites via recognition of posttranslational modifications (PTMs) on N-terminal tails of histone proteins (e.g., methylation, acetylation, and phosphorylation). Molecular recognition of modified histones is mediated by “reader” protein subunits. The recruited complexes govern processes such as gene transcription, DNA replication, and chromatin remodeling. Dysregulation of histone modifications and consequent downstream effects have been associated with a variety of disease states, leading to an interest in developing small-molecule inhibitors of reader proteins. Herein, we describe a generalized time-resolved fluorescence resonance energy transfer (TR-FRET) assay for a panel of methyl-lysine (Kme) reader proteins. These assays are facile, robust, and reproducible. Importantly, this plug-and-play assay can be used for high-throughput screening (HTS) campaigns, generation of structure–activity relationships (SARs), and evaluation of inhibitor selectivity. Successful demonstration of this assay format for compound screening is highlighted with a pilot screen of a focused compound set with CBX2. This assay platform enables the discovery and characterization of chemical probes that can potently and selectively inhibit Kme reader proteins to ultimately accelerate studies of chromatin reader proteins in normal biology and disease states.

9 October 2015 in Journal of the American Chemical Society
Verified
Journal Article
Closed access
NLNicholas D. Lanz
Nicholas D. Lanz
JRJustin Rectenwald
Justin Rectenwald
BWBo Wang
Bo Wang
EKElizabeth S. Kakar
Elizabeth S. Kakar
TLTatiana N. Laremore
Tatiana N. Laremore
ASAlexey Silakov
Alexey Silakov

22 February 2020 in Molecules
Verified
Journal Article
Open access
PDF file
JRJustin Rectenwald
Justin Rectenwald
SGShiva Krishna Reddy Guduru
Shiva Krishna Reddy Guduru
ZDZhao Dang
Zhao Dang
LCLeonard B. Collins
Leonard B. Collins
YLYi-En Liao
Yi-En Liao
Kenneth PearceKenneth Pearce
Kenneth Pearce
Chromatin structure and function, and consequently cellular phenotype, is regulated in part by a network of chromatin-modifying enzymes that place post-translational modifications (PTMs) on histone tails. These marks serve as recruitment sites for other chromatin regulatory complexes that ‘read’ these PTMs. High-quality chemical probes that can block reader functions of proteins involved in chromatin regulation are important tools to improve our understanding of pathways involved in chromatin dynamics. Insight into the intricate system of chromatin PTMs and their context within the epigenome is also therapeutically important as misregulation of this complex system is implicated in numerous human diseases. Using computational methods, along with structure-based knowledge, we have designed and constructed a focused DNA-Encoded Library (DEL) containing approximately 60,000 compounds targeting bi-valent methyl-lysine (Kme) reader domains. Additionally, we have constructed DNA-barcoded control compounds to allow optimization of selection conditions using a model Kme reader domain. We anticipate that this target-class focused approach will serve as a new method for rapid discovery of inhibitors for multivalent chromatin reader domains.

21 June 2019 in bioRxiv
Verified
Preprint
Open access
PDF file
FPFrances Potjewyd
Frances Potjewyd
ATAnne-Marie W. Turner
Anne-Marie W. Turner
JBJoshua Beri
Joshua Beri
JRJustin Rectenwald
Justin Rectenwald
JNJacqueline L. Norris-Drouin
Jacqueline L. Norris-Drouin
LJLindsey Ingerman James
Lindsey Ingerman James
SUMMARY: Protein degradation via the use of bivalent chemical degraders provides an alternative strategy to block protein function and assess the biological roles of putative drug targets. This approach capitalizes on the advantages of small molecule inhibitors while moving beyond the restrictions of traditional pharmacology. Herein we report a first-in-class chemical degrader (UNC6852) that targets Polycomb Repressive Complex 2 (PRC2). UNC6852 contains an EED226 derived ligand and a ligand for VHL which bind to the WD40 aromatic cage of EED and CRL2 VHL , respectively, to induce proteasomal degradation of PRC2 components, EED, EZH2, and SUZ12. Degradation of PRC2 with UNC6852 blocks the histone methyltransferase activity of EZH2, decreasing H3K27me3 levels in HeLa cells and diffuse large B-cell lymphoma (DLBCL) cells containing an EZH2 Y641N gain-of-function mutation. UNC6852 degrades both wild type EZH2 and EZH2 Y641N , and additionally displays anti-proliferative effects in this cancer model system. Abstract Figure:

1 January 2019 in SSRN Electronic Journal
Verified
Preprint
Open access
PDF file
FPFrances Potjewyd
Frances Potjewyd
ATAnne-Marie Turner
Anne-Marie Turner
JBJoshua Beri
Joshua Beri
JRJustin Rectenwald
Justin Rectenwald
JNJacqueline Norris-Drouin
Jacqueline Norris-Drouin
LJLindsey Ingerman James
Lindsey Ingerman James
Protein degradation via the use of bivalent chemical degraders provides an alternative strategy to block protein function and assess the biological roles of putative drug targets. This approach capitalizes on the advantages of small molecule inhibitors while moving beyond the restrictions of traditional pharmacology. Herein we report a first-in-class chemical degrader (UNC6852) that targets Polycomb Repressive Complex 2 (PRC2). UNC6852 contains an EED226 derived ligand and a ligand for VHL which bind to the WD40 aromatic cage of EED and CRL2VHL, respectively, to induce proteasomal degradation of PRC2 components, EED, EZH2, and SUZ12. Degradation of PRC2 with UNC6852 blocks the histone methyltransferase activity of EZH2, decreasing H3K27me3 levels in HeLa cells and diffuse large B-cell lymphoma (DLBCL) cells containing an EZH2Y641N gain-of-function mutation. UNC6852 degrades both wild type EZH2 and EZH2Y641N, and additionally displays anti-proliferative effects in this cancer model system.